← Back to Search

Topical CBD for Skin Health (cannabidiol Trial)

N/A
Waitlist Available
Research Sponsored by Penn State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up ~5 hours
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

This trial studied the effects of topical CBD on healthy adults, finding it may help with pain, recovery, and general wellness.

Who is the study for?
This trial is for English-speaking men and women aged 18 or older with a BMI ≤ 39.9 and normal blood sugar levels (HbA1C <6.5%). It's not suitable for those with diabetes, drug use, pregnant/breastfeeding women, abnormal heart rates/BP, skin conditions/allergies, nicotine users, or recent CBD users.
What is being tested?
The study tests the effect of topical Cannabidiol (CBD) on skin vascular reactivity using iontophoresis in healthy adults. The goal is to see if CBD can reduce the increased blood flow response that happens when the skin is stimulated.
What are the potential side effects?
While specific side effects are not listed for this trial, common side effects of topical CBD may include mild irritation at the application site. Since it's used externally and by healthy individuals here, significant side effects are less expected.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~~5 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and ~5 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cutaneous Vascular Conductance

Side effects data

From 2022 Phase 2 & 3 trial • 90 Patients • NCT04387617
29%
Tiredness
20%
Constipation
18%
Drowsiness
11%
Poor sleep
11%
Dizziness
9%
Poor Appetite
9%
Headache
4%
Nausea
4%
Itching
2%
Diarrhea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Control Group
CBD Oil Group

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CannabidiolExperimental Treatment1 Intervention
Active ingredient experimental arm, contains full spectrum connabidiol
Group II: PlaceboPlacebo Group1 Intervention
Vehicle control, does not contain cannabidiol
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cannabidiol
FDA approved

Find a Location

Who is running the clinical trial?

Penn State UniversityLead Sponsor
368 Previous Clinical Trials
127,544 Total Patients Enrolled
~32 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top